With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Our aim was to summarize published secondary analyses of the PARADIGM‐HF trial. In the
original trial, published in September 2014, sacubitril/valsartan significantly reduced the …

It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …

Background: The net clinical benefit of cardiac disease-modifying drugs might be influenced
by the interaction of different domains of disease burden. We assessed the relative …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Background Sacubitril/valsartan significantly reduced heart failure hospitalization and
mortality in PARADIGM‐HF (Prospective Comparison of Angiotensin Receptor‐Neprilysin …

Abstract The Prospective Comparison of Angiotensin Receptor Antagonist and Neprilysin
Inhibitor with Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …